PharmaJet launched a study in Nigeria to evaluate the intradermal administration of a fractional inactivated poliovirus vaccine (fIPV) using the company’s Tropis ID Needle-free Injection System.
Children at 22 urban and rural health facilities will receive the vaccine via Tropis. The study will assess coverage rates and the potential for reduced costs associated with using Tropis for flPV delivery, as compared to the current standard of intramuscular delivery via needle and syringe. The study is intended to inform policy regarding intradermal delivery of polio vaccine in routine immunization settings.
“We are pleased to be collaborating with NPHCDA, Jhpiego, PATH and Sydani Group on this important innovative routine immunization program in Nigeria,” Paul LaBarre, PharmaJet’s vice president of global business development, said in a statement. “Including additional campaigns in Somalia, we have provided more than 10-million syringes for polio immunization programs. On this World Polio Day 2023, we restate our commitment to the Global Polio Eradication Initiative.”
The study is being conducted in collaboration with the National Primary Health Care Development Agency (NPHCDA), Jhpiego, PATH and the Sydani Group.
